COVID-19 rebound after oral treatment in a nursing home facility: A case series

Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2-8 days after completing the treatment cour...

Full description

Saved in:
Bibliographic Details
Published in:Infectious medicine 2022, Vol.1 (4), p.285-287
Main Authors: Betrosian, Alex P, Christou, Stavros M, Kalathaki, Stavroula
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 287
container_issue 4
container_start_page 285
container_title Infectious medicine
container_volume 1
creator Betrosian, Alex P
Christou, Stavros M
Kalathaki, Stavroula
description Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2-8 days after completing the treatment course has been recently recognized. In some cases patients tested negative on a direct SARS-CoV-2 viral test and then tested positive again (rebound COVID-19). The disease is mild and requires no additional antiviral treatment. Data are limited based on anecdotal case reports and few studies. According to the available data it is unclear if rebound symptoms are due to the drug treatment, drug resistance, re-infection or impaired immunity.
doi_str_mv 10.1016/j.imj.2022.10.003
format report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2894723693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2894723693</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_28947236933</originalsourceid><addsrcrecordid>eNqVyrFuwjAQgGELqVIR5QG63ciS1D5HCWargKqdsiDUDbnhAo4cm_qcgbdvh75Ap1-f9AvxrGSppKpfhtKNQ4kS8dellHom5tg0WFRafT6KJfMgpUSjtEE9F-22PX7sCmUg0VecwhlsnylBTNZDTmTzSCGDC2AhTIlduMA1jgS97Zx3-b6BV-gsEzAlR_wkHnrrmZZ_XYjV2_6wfS9uKX5PxPk0Ou7IexsoTnzCtaka1LXR-h_rDw5jRyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2894723693</pqid></control><display><type>report</type><title>COVID-19 rebound after oral treatment in a nursing home facility: A case series</title><source>ScienceDirect</source><source>PMC (PubMed Central)</source><creator>Betrosian, Alex P ; Christou, Stavros M ; Kalathaki, Stavroula</creator><creatorcontrib>Betrosian, Alex P ; Christou, Stavros M ; Kalathaki, Stavroula</creatorcontrib><description>Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2-8 days after completing the treatment course has been recently recognized. In some cases patients tested negative on a direct SARS-CoV-2 viral test and then tested positive again (rebound COVID-19). The disease is mild and requires no additional antiviral treatment. Data are limited based on anecdotal case reports and few studies. According to the available data it is unclear if rebound symptoms are due to the drug treatment, drug resistance, re-infection or impaired immunity.</description><identifier>EISSN: 2772-431X</identifier><identifier>DOI: 10.1016/j.imj.2022.10.003</identifier><language>eng</language><ispartof>Infectious medicine, 2022, Vol.1 (4), p.285-287</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>777,781,4476,27906</link.rule.ids></links><search><creatorcontrib>Betrosian, Alex P</creatorcontrib><creatorcontrib>Christou, Stavros M</creatorcontrib><creatorcontrib>Kalathaki, Stavroula</creatorcontrib><title>COVID-19 rebound after oral treatment in a nursing home facility: A case series</title><title>Infectious medicine</title><description>Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2-8 days after completing the treatment course has been recently recognized. In some cases patients tested negative on a direct SARS-CoV-2 viral test and then tested positive again (rebound COVID-19). The disease is mild and requires no additional antiviral treatment. Data are limited based on anecdotal case reports and few studies. According to the available data it is unclear if rebound symptoms are due to the drug treatment, drug resistance, re-infection or impaired immunity.</description><issn>2772-431X</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2022</creationdate><recordtype>report</recordtype><recordid>eNqVyrFuwjAQgGELqVIR5QG63ciS1D5HCWargKqdsiDUDbnhAo4cm_qcgbdvh75Ap1-f9AvxrGSppKpfhtKNQ4kS8dellHom5tg0WFRafT6KJfMgpUSjtEE9F-22PX7sCmUg0VecwhlsnylBTNZDTmTzSCGDC2AhTIlduMA1jgS97Zx3-b6BV-gsEzAlR_wkHnrrmZZ_XYjV2_6wfS9uKX5PxPk0Ou7IexsoTnzCtaka1LXR-h_rDw5jRyQ</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Betrosian, Alex P</creator><creator>Christou, Stavros M</creator><creator>Kalathaki, Stavroula</creator><scope>7X8</scope></search><sort><creationdate>20221201</creationdate><title>COVID-19 rebound after oral treatment in a nursing home facility: A case series</title><author>Betrosian, Alex P ; Christou, Stavros M ; Kalathaki, Stavroula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_28947236933</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Betrosian, Alex P</creatorcontrib><creatorcontrib>Christou, Stavros M</creatorcontrib><creatorcontrib>Kalathaki, Stavroula</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Betrosian, Alex P</au><au>Christou, Stavros M</au><au>Kalathaki, Stavroula</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>COVID-19 rebound after oral treatment in a nursing home facility: A case series</atitle><jtitle>Infectious medicine</jtitle><date>2022-12-01</date><risdate>2022</risdate><volume>1</volume><issue>4</issue><spage>285</spage><epage>287</epage><pages>285-287</pages><eissn>2772-431X</eissn><abstract>Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2-8 days after completing the treatment course has been recently recognized. In some cases patients tested negative on a direct SARS-CoV-2 viral test and then tested positive again (rebound COVID-19). The disease is mild and requires no additional antiviral treatment. Data are limited based on anecdotal case reports and few studies. According to the available data it is unclear if rebound symptoms are due to the drug treatment, drug resistance, re-infection or impaired immunity.</abstract><doi>10.1016/j.imj.2022.10.003</doi></addata></record>
fulltext fulltext
identifier EISSN: 2772-431X
ispartof Infectious medicine, 2022, Vol.1 (4), p.285-287
issn 2772-431X
language eng
recordid cdi_proquest_miscellaneous_2894723693
source ScienceDirect; PMC (PubMed Central)
title COVID-19 rebound after oral treatment in a nursing home facility: A case series
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=COVID-19%20rebound%20after%20oral%20treatment%20in%20a%20nursing%20home%20facility:%20A%20case%20series&rft.jtitle=Infectious%20medicine&rft.au=Betrosian,%20Alex%20P&rft.date=2022-12-01&rft.volume=1&rft.issue=4&rft.spage=285&rft.epage=287&rft.pages=285-287&rft.eissn=2772-431X&rft_id=info:doi/10.1016/j.imj.2022.10.003&rft_dat=%3Cproquest%3E2894723693%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_28947236933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2894723693&rft_id=info:pmid/&rfr_iscdi=true